Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
Access expired on Monday, March 25, 2019

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

Register Now
featured
Published in Oncology

Expert Opinion / Interview · February 22, 2019

A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelial Carcinoma

Sumanta Pal MD
Guru Sonpavde MD
Interview with
Guru P. Sonpavde MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Sumanta Pal MD

Guru Sonpavde MD

Further Reading

Related Videos